USPTO 2015–2025 USPTO PatentsView US Corporation

Element Biosciences, Inc.

USPTO PatentsView assignee record - 41 granted patents across 11 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Element ranks #7,837 of 49,997 tracked US assignees by granted-patent volume, with 41 patents across 11 technology areas.

#7,837
of 49,997 US assignees by volume
Top 4%
by Innovation Score (59.6/100)
25.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R7837 · US Corporation #7,837 · 41 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-SMALL 41 grants
  • UPPER-Q #7,837/49,997
  • PHOTO-FINISH ConcealFab
  • CPC-FOCUS C12Q · 11 areas
  • INNOV-PAR 59.6/100
  • CLAIMS-DENSE 25.2 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2020–2025 · 6y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: ConcealFab, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Element’s 59.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Element

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Element's Innovation Score is 59.6/100 (top 4% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Element?

Each dot is one of Element’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Element’s own 25.2 claims/patent is ABOVE the 11.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Element vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 40.941.041.04141.041.041.1 01020304050 Granted patents (volume) Avg claims / patent ConcealFab, Inc. - 41, 8.1ConcealfabConstellation Designs, LLC - 41, 47.9Constellation Des…Cujo LLC - 41, 18.17CujoDuPont Teijin Films U.S. Limited Partnership - 41, 27.46Dupont Teijin Fil…Exact Sciences Development Company, LLC - 41, 10.39Exact Sciences De…Fine M-tec Co., Ltd - 41, 11.51Fine M-tecFormosa Epitaxy Incorporation - 41, 8.34Formosa Epitaxy I…Fujifilm Toyama Chemical Co., Ltd. - 41, 11.78Fujifilm Toyama C…Element Biosciences, Inc. - 41, 25.24Element Bioscienc…
Element vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Element's grants concentrate

Element Biosciences, Inc. is a focused PatentsView assignee: 11 CPC subclasses with 90.2% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2022 (12 grants) versus a trough of 3 in 2020. By volume, Element sits between ConcealFab, Inc. and Fujifilm Toyama Chemical Co., Ltd..

Element's three-year grant acceleration

Element Biosciences, Inc. shows 24 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Element's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Element holds 41 patents at rank #7,837, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Element

By rank, the assignees closest to #7,837 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Element's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Element, neither rank-band nor same-CPC leaders (those blocks stay above). In C12Q (Measuring OR Testing Processes Involving Enzymes), Element ranks #123 of 2,502 assignees by patent count in that subclass.

Element's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

60 Top 4% higher than 96% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

2468101214 202020212022202320242025 9
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Element Biosciences, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 3 7.3%
2021 5 12.2%
2022 12 29.3%
2023 3 7.3%
2024 9 22.0%
2025partial year 9 22.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Element Biosciences, Inc.'s patent record in context - here's where to go next.

  • Element Biosciences, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 90.2% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #7,837 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Element Biosciences, Inc. against ConcealFab, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 59.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.